In recent years, there has been rapid economic growth in some developing countries, which is seen as a new market opportunity for businesses, however, these countries are disadvantaged by their limited access to medical resources. In particular, they are significantly handicapped by the three major infectious diseases i.e. HIV/AIDS, Tuberculosis, Malaria, and NTD (Neglected Tropical Diseases)
As public funding is limited, an innovative business model called “Public-Private-Partnership”(PPP) plays an important role in solving global health issues in developing countries. PPP is a government service or private business venture, which is funded and operated through a partnership of government and one or more private sector companies.
In the first session of the current sequential seminars, the discussion focused on why PPP has drawn great attention especially in the global health field. By introducing examples of PPP by The Global Health Innovative Technology Fund (GHIT Fund,), which aims to solve global health issues, discussion continued on how government and private sector companies can cooperate and maximize such partnership.

In the second session, three professionals from three different institutions were invited as main speakers. The institutions are the Bill and Melinda foundation, which plays a significant role in global health, Medicines for Malaria Venture (MMV), which takes an initiative for development and research for Malaria related pharmaceutical goods and vaccines, and AERAS, which focuses on R&D for tuberculosis. The seminar aims to introduce the current situation of Global Health R&D, PDP, social corporate responsibility of private companies, lessons learnt from overseas examples, and to discuss Japan’s role as a catalyst to hasten development of pharmaceutical goods in developing countries.


*PDP(Product Development Partnership) refers to international partnerships specific to pharmaceutical development for infectious disease, clinical trials and production of necessary materials. There are about 20 PDPs around the world including pharmaceutical development for HIV, malaria, TB, neglected tropical diseases, vaccine, R&D for diagnostic pharmaceutical and clinical trials around the world. MMV and AERAS are the most prominent examples of PDP.

*More details is here.


Information
■Date and Time
December 3rd, 2013 19:30−21:30　

■Theme
Key player in Global Health Research and Development

■Speakers
Dr. Hannah Kettler(Global health, Life science partnership, Senior Program Officer, The Bill & Melinda Gates Foundation)

Dr. Andrea Lucard (Executive Vice-president, External Relations, Medicines for Malaria Venture)

Dr. Sharon Chan (Head ASIA, AERAS)

■Host
Health and Global Policy Institute, Global Health Innovative Technology Fund

■Cooperation
MORI Building Co.,Ltd

■Targeted Audience    Open for 70 attendees
Business persons and researchers who aim to contribute to medical drug development for developing countries, people from NPO, public administrations, international organizations, students and so on.

■Fee：    1500yen (Students 1000yen) for each session

■Venue
Academy Hills Sky Studio

6-10-1, Roppongi, Minato-ku, Tokyo, 106-6149
Roppongi Hills Mori Tower 49F
http://www.academyhills.com/aboutus/access/index.html


■Language
English (Simultaneous translation will be provided at the venue)

■Organizer
Health and Global Policy Institute (HGPI）
Since its establishment in 2004, the Health and Global Policy Institute (HGPI) has been working to help interested citizens shape health policies by generating policy options and bringing stakeholders together as a nonpartisan think tank. HGPI’s mission is to improve civic and individual well being and to foster as sustainable healthy community by shaping ideas and values, reaching out to global needs, and catalyzing society for impact. HGPI commits to activities that bring together relevant players in different fields to provide innovative and practical solutions and help interested citizens understand choices and benefits in a global, long-term perspective. HGPI promotes a Global Citizen Nation by building a society for people with various backgrounds and different values. It aims to achieve a sustainable, healthy, and more prosperous world.

Global Health Innovative Technology Fund (GHIT Fund)
The Global Health Innovative Technology Fund (GHIT Fund) is Japan’s first public-private partnership to advance the development of new health technologies for the developing world. The first product development fund of its kind in Japan, the GHIT Fund was created by the Japanese Government, Japan’s leading pharmaceutical companies, and the Bill & Melinda Gates Foundation. The GHIT Fund is bringing Japanese leadership in health and technology innovation from its public and private sectors to the global fight against infectious diseases. The goals is to facilitate and fund global health R&D partnerships that can generate new drugs,vaccines and diagnostics and other tools for fighting neglected diseases prevalent in developing world (ghitfund.org/en)

——–
Inquiry
Health and Global Policy Institute
Tel: 03-5511-8521
Email: info@hgpi.org

Exhibition date：2013-12-03